Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback